At Foundation Medicine, we are strong believers in the power of a community to make change. The sharing of ideas, opinions, stories, and discoveries can lead to new insights and important connections that wouldn’t otherwise be made. The transformation in cancer care is no different. Through Foundation Forward, we hope to create a community where we can support and challenge each other through conversations, discussions and storytelling, and work together to move the field of oncology forward.

Completing the Puzzle for Colorectal Cancer

Each person and each cancer is unique, and the goal of precision medicine is to uncover this individuality. For colorectal cancer (CRC), we have discovered a few important pieces of the puzzle, but the entire picture is incomplete. There is an urgent need to discover more specific predictive markers of CRC that can improve outcomes, and for an approach that delivers every piece of the puzzle at once. Comprehensive genomic profiling (CGP) may be part of the solution.

Read More

Shaping the Future of Liquid Biopsies

At Foundation Medicine, we firmly believe that precision medicine is the future of cancer care. And if we want to make this future a reality, we need collaboration. Collaboration across multiple partners is essential to realizing the full potential of innovative new technologies that may change the way we identify and treat cancer. One of these new technologies is a blood-based genomic profiling assay, also known as liquid biopsy.

Read More

Foundation Medicine’s First FDA-Approved Companion Diagnostic May Improve Outcomes for Women with Ovarian Cancer

Today, Foundation Medicine introduced FoundationFocus™ CDxBRCA, our first product to be approved by the U.S. Food and Drug Administration (FDA). This companion diagnostic is intended to aid in identifying women with ovarian cancer for whom treatment with Rubraca™ (rucaparib) tablets, a therapy developed by Clovis Oncology, Inc., is being considered. Rubraca is an FDA-approved monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It belongs to a class of cancer drugs called poly-ADP-ribose polymerase (PARP) inhibitors.

Read More

Helping Blood Cancer Patients of All Ages: Why We’re at ASH 2016

Blood cancers have helped shape the evolution of cancer treatment from the beginning. As early as World War II, the first chemotherapies were developed to help people living with lymphoma.1 Following those early approaches, we’ve experienced a revolution in our understanding of the genomic drivers of hematologic malignancies that has led to the development of a range of new targeted therapies. With recent advances in comprehensive genomic profiling (CGP), we are now poised to further impact the treatment landscape for blood cancers.

Read More

Newly published data support TMB as a predictor for anti-PD-1/PD-L1 response in melanoma

Over 144,000 Americans are expected to be diagnosed with melanoma this year.1 With a 15-20% 5-year survival rate for Stage IV patients, the future is not always optimistic.2 Thankfully, immunotherapy is changing that outlook. For example, one recent study found that an anti-PD-1 therapy doubled the survival rate in advanced melanoma cases.3

Still, immunotherapies may not work for everyone. Read More